ライフサイエンスコーパス: hyperactivity

1 the first year, that could recover the vagal hyperactivity.

2 promoting kidney cysts in conditions of mTOR hyperactivity.

3 grafts (PDXs) was also associated with TORC1 hyperactivity.

4 cocaine pharmacokinetics or cocaine-induced hyperactivity.

5 food self-administration or cocaine-induced hyperactivity.

6 ankyrin-G ubiquitination and aggregation and hyperactivity.

7 une abnormalities consistent with lymphocyte hyperactivity.

8 imilar behavioral profile when we induce CA3 hyperactivity.

9 FDA-approved drug memantine, abrogated this hyperactivity.

10 tion mechanistic basis for cancer-associated hyperactivity.

11 sition to sarcopenia correlating with mTORC1 hyperactivity.

12 ed by body axis and swim bladder defects and hyperactivity.

13 ations that do not affect activity or induce hyperactivity.

14 A_Stow, that appear to be critical for mPing hyperactivity.

15 nique period of apparent healthy sympathetic hyperactivity.

16 stent with previous reports linking NPY with hyperactivity.

17 obox protein 2, and MSEW-induced anxiety and hyperactivity.

18 at are associated with excessive anxiety and hyperactivity.

19 rough its receptor (RAR), is the trigger for hyperactivity.

20 talytic site, thereby intrinsically inducing hyperactivity.

21 c+ mice and partially rescued the behavioral hyperactivity.

22 ing effects observed were not accompanied by hyperactivity.

23 ignals to manage conditions like anxiety and hyperactivity.

24 king OFC-DMS potentiation to cocaine-induced hyperactivity.

25 lysosome-borne activators, leading to mTORC1 hyperactivity.

26 um channel Na(v) 1.6 that result in neuronal hyperactivity.

27 stimulant drug methylphenidate mitigated the hyperactivity.

28 In neuronal cell-based models of mTOR hyperactivity, 7 corrected the mTOR pathway activity and

29 n Alzheimer's disease (AD), Abeta-associated hyperactivity accelerates the progression of pathologica

30 t functional neuroimaging findings implicate hyperactivity across the prefrontal cortex (PFC) and str

31 autism spectrum (ASD) and attention deficit hyperactivity (ADHD) disorders.

32 ty maintain a depolarized RMP and nociceptor hyperactivity after SCI, providing a self-reinforcing me

33 Our data reveal that S6K1 hyperactivity alters centrosome positioning in mitotic c

34 CK1delta (CK1delta OE) in the forebrain show hyperactivity and ADHD-like pharmacological responses to

35 Other defects, however, such as periods of hyperactivity and alterations in place preference, are n

36 ism and schizophrenia, exhibit mitochondrial hyperactivity and altered group behavior.

37 ptor signaling, regulate behaviors including hyperactivity and attention by inducing new synapse form

38 y leads to profound motor changes resembling hyperactivity and attention deficit.

39 zed by neuropsychiatric phenotypes including hyperactivity and bipolar disorder as well as epilepsy.

40 After SCI, DRG neurons show hyperactivity and chronic depolarization of resting memb

41 and that compensatory plasticity limits STN hyperactivity and cortical entrainment.

42 Hyperactivity and disturbances of attention are common b

43 of B cell signaling is important to prevent hyperactivity and dysregulation of the immune response.

44 The relationship between hippocampal hyperactivity and early AD molecular pathology (amyloid-

45 ogenously activated to sustain NMDA receptor hyperactivity and elevated sympathetic outflow via PKC i

46 eral nares blockade reduced ketamine-induced hyperactivity and HFO power and frequency.

47 on is known be effective in changing network hyperactivity and hypersynchronziation.

48 but not tau, in the emergence of EC neuronal hyperactivity and impaired theta rhythmicity.

49 ibitory interneurons led to pyramidal neuron hyperactivity and increased stimulus sensitivity in the

50 Hypothalamic-pituitary-adrenal (HPA)-axis hyperactivity and inflammation are thought to be promine

51 Desflurane did not induce behavioral hyperactivity and isoflurane only caused behavioral hype

52 , while compensatory plasticity prevents STN hyperactivity and limits cortical entrainment.

53 e in freely behaving rats led to macro-scale hyperactivity and micro-scale behavioral transitions, sy

54 rminant of afferent hyperexcitability, organ hyperactivity and pain.

55 The hyperactivity and reduced sociability, but not the suppr

56 SSRIs induce SNr hyperactivity and SNc hypoactivity that can also be reve

57 V) inhibitory interneuron activity underlies hyperactivity and SWR disruption.

58 ith biallelic mutations of TSC2 demonstrated hyperactivity and transcriptional dysregulation observed

59 ) whose rate determined the magnitude of the hyperactivity and whose timing corresponded to unitary b

60 In addition, the offspring showed locomotor hyperactivity and working memory deficit not observed in

61 and/or attenuate cocaine-induced reward and hyperactivity and, thus, decrease cocaine self-administr

62 triction activates SIRT1, promoting anxiety, hyperactivity, and addiction to starvation, exacerbating

63 festations including seizure susceptibility, hyperactivity, and anxiety/compulsivity, which can be re

64 ty, including autism traits, inattention and hyperactivity, and ataxia, who carries a de novo framesh

65 istically displayed intellectual disability, hyperactivity, anxiety, and abnormal sensory processing.

66 It is not known if Depdc5cc+ mice have a hyperactivity/anxiety phenotype, die early from terminal

67 to T cell dysregulation associated with IFN hyperactivity as a contributor to autoimmunity in DS.

68 rmalin injection reveals persistent neuronal hyperactivity associated with ongoing pain.

69 ion, abnormal ventroflexion of the tail, and hyperactivity at nonteratogenic concentrations.

70 LMW) were associated with more self-reported hyperactivity [beta = 0.8, 95% confidence interval (CI):

71 ion of preclinical AD that place hippocampal hyperactivity concurrent with spread of tau pathology to

72 re mechanistic studies to determine how mPFC hyperactivity contributes to OCD-relevant cognitive dysf

73 y for maintaining ongoing depolarization and hyperactivity, demonstrating an unexpected positive feed

74 DG-GluN1 KO mice show CA3 cellular hyperactivity, detected using two approaches: (1) increa

75 trum disorder (ASD) and/or attention deficit hyperactivity disorder (ADHD) and 5,000 controls were an

76 diator between symptoms of attention deficit hyperactivity disorder (ADHD) and associated cognitive a

77 P), major depression (MD), attention-deficit hyperactivity disorder (ADHD) and autism (AUT).

78 netic loci associated with attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disord

79 phen exposure and risks of attention deficit hyperactivity disorder (ADHD) and autism spectrum disord

80 Attention-Deficit/Hyperactivity Disorder (ADHD) and conduct disorder (CD)

81 that children treated for attention deficit hyperactivity disorder (ADHD) and depression have more s

82 nic risk scores (PRSs) for attention deficit hyperactivity disorder (ADHD) and depression, derived us

83 xcessive mind wandering in attention-deficit/hyperactivity disorder (ADHD) and its association with i

84 frequently co-occurs with attention-deficit/hyperactivity disorder (ADHD) and often leads to antisoc

85 atric disorders, including attention deficit hyperactivity disorder (ADHD) and, more recently, Autism

86 tism spectrum disorder and attention-deficit/hyperactivity disorder (ADHD) are associated with comple

87 Individuals with attention deficit hyperactivity disorder (ADHD) are at increased risk for

88 pulsive disorder (OCD) and attention-deficit/hyperactivity disorder (ADHD) are clinically and biologi

89 anxiety, irritability, and attention-deficit/hyperactivity disorder (ADHD) as common, impactful, co-o

90 n the etiology of clinical attention-deficit/hyperactivity disorder (ADHD) diagnoses and symptoms in

91 amine for the treatment of attention deficit-hyperactivity disorder (ADHD) has been increasing.

92 Although the prevalence of attention-deficit/hyperactivity disorder (ADHD) has been stable over the p

93 spectrum disorder (ASD) or attention deficit hyperactivity disorder (ADHD) have 2-3 times increased h

94 Previous studies of attention-deficit hyperactivity disorder (ADHD) have suggested that struct

95 p) vaccination and risk of attention-deficit/hyperactivity disorder (ADHD) in offspring.

96 Attention deficit/hyperactivity disorder (ADHD) is a common and heritable

97 Attention deficit hyperactivity disorder (ADHD) is a common and highly her

98 Attention-deficit/hyperactivity disorder (ADHD) is a common and impairing

99 Attention-Deficit/Hyperactivity Disorder (ADHD) is a common neurodevelopme

100 Attention deficit/hyperactivity disorder (ADHD) is a common neurodevelopme

101 Attention deficit hyperactivity disorder (ADHD) is a common neuropsychiatr

102 Attention deficit hyperactivity disorder (ADHD) is a common, highly herita

103 Attention deficit hyperactivity disorder (ADHD) is a highly heritable psyc

104 Attention-deficit/hyperactivity disorder (ADHD) is a major sequela of trau

105 Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental di

106 Attention-deficit/hyperactivity disorder (ADHD) is a risk factor for suici

107 Attention-deficit/hyperactivity disorder (ADHD) is a severely impairing ne

108 Attention-deficit/hyperactivity disorder (ADHD) is an impairing neurodevel

109 Attention-deficit hyperactivity disorder (ADHD) is associated with pervasi

110 Attention-deficit/hyperactivity disorder (ADHD) is emblematic of the probl

111 ated change in symptoms of attention-deficit/hyperactivity disorder (ADHD) is heritable.

112 es (PFAS) exposure and attention deficit and hyperactivity disorder (ADHD) is inconclusive.

113 ment might protect against attention-deficit hyperactivity disorder (ADHD) or moderate the symptoms o

114 Symptoms of attention-deficit/hyperactivity disorder (ADHD) run a variable course thro

115 Childhood attention deficit hyperactivity disorder (ADHD) shows a highly variable co

116 scores (PRSs) for ASD and attention-deficit/hyperactivity disorder (ADHD) using genome-wide associat

117 tive mechanisms underlying attention-deficit hyperactivity disorder (ADHD), a highly heritable disord

118 ldren and adolescents with attention deficit hyperactivity disorder (ADHD), as frequently prescribed

119 Attention deficit hyperactivity disorder (ADHD), autism spectrum disorder

120 ciation studies (TWASs) of attention deficit hyperactivity disorder (ADHD), autism spectrum disorder,

121 nconstant features include attention-deficit/hyperactivity disorder (ADHD), autism, mild facial dysmo

122 Attention-deficit hyperactivity disorder (ADHD), like other psychiatric di

123 ter among individuals with attention-deficit/hyperactivity disorder (ADHD), potentially due to defici

124 pectrum disorder (ASD) and attention-deficit hyperactivity disorder (ADHD), the entire range of neuro

125 ating depression, anxiety, attention-deficit hyperactivity disorder (ADHD), Tourette syndrome, post-t

126 sed with schizophrenia and attention deficit hyperactivity disorder (ADHD), which share attentional i

127 ity (HRV) in children with Attention-Deficit/Hyperactivity Disorder (ADHD).

128 c variants confer risk for attention deficit hyperactivity disorder (ADHD).

129 all cognition in boys with attention deficit hyperactivity disorder (ADHD).

130 al changes associated with attention-deficit/hyperactivity disorder (ADHD).

131 articularly drug abuse and attention-deficit/hyperactivity disorder (ADHD).

132 ed with the development of attention-deficit/hyperactivity disorder (ADHD).

133 pectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD).

134 ducational attainment, and attention deficit hyperactivity disorder (ADHD).

135 ldren and adolescents with attention-deficit/hyperactivity disorder (ADHD).

136 autism spectrum disorder, attention deficit hyperactivity disorder (ADHD)] in children of preeclampt

137 yslexia risk with PGSs for attention deficit hyperactivity disorder (at p(T) = 0.05 in the training G

138 17; n unique genes = 13), attention deficit hyperactivity disorder (n associations = 19; n unique ge

139 depressive disorder [MDD], attention deficit/hyperactivity disorder [ADHD], bipolar disorder, schizop

140 ders were observed in both attention-deficit/hyperactivity disorder and autism spectrum disorder.

141 opmental disorders such as attention deficit hyperactivity disorder and autism spectrum disorder.

142 frequent association with attention deficit hyperactivity disorder and impulse control disorders.

143 ng from childhood, such as attention deficit hyperactivity disorder and intellectual disability, to l

144 lation in association with Attention Deficit Hyperactivity Disorder and Mental Development Index at a

145 ssive-compulsive disorder, attention deficit hyperactivity disorder and Tourette's syndrome.

146 enia, bipolar disorder and attention-deficit/hyperactivity disorder are located in protein-coding exo

147 l age in later symptoms of attention-deficit/hyperactivity disorder in 105 individuals (49 males and

148 , aggressive behavior, and attention-deficit/hyperactivity disorder in children were assessed using m

149 disorders, depression and attention deficit hyperactivity disorder in independent clinical samples.

150 predicts later symptoms of attention-deficit/hyperactivity disorder in the euploid population, this h

151 Attention-deficit/hyperactivity disorder is frequently reported in individ

152 ive behavior symptoms, and attention-deficit/hyperactivity disorder symptoms within the borderline/cl

153 , aggressive behavior, and attention-deficit/hyperactivity disorder symptoms, a one-unit increase in

154 udy meta-analysis of adult attention-deficit/hyperactivity disorder symptoms, based on peripheral blo

155 (IQ) and higher levels of attention deficit/hyperactivity disorder symptoms.

156 iated with lower levels of attention deficit/hyperactivity disorder symptoms.

157 n when cases with comorbid attention-deficit/hyperactivity disorder were removed from the analysis.

158 ility, facial dysmorphism, attention-deficit hyperactivity disorder) and revealed further disease mec

159 (autism spectrum disorders/attention deficit hyperactivity disorder).

160 ease, schizophrenia, and attention deficient-hyperactivity disorder, and abnormalities in social memo

161 ase, schizophrenia, attention deficiency and hyperactivity disorder, and addiction.

162 disorder, cross disorder, attention-deficit/hyperactivity disorder, and anorexia nervosa) and 17 non

163 en considering symptoms of attention-deficit/hyperactivity disorder, as it may have implications for

164 adults, including autism, attention deficit hyperactivity disorder, asthma, and allergies.

165 iatric disorders including attention deficit hyperactivity disorder, autism and bipolar disorder(2,5)

166 disability, schizophrenia, attention-deficit hyperactivity disorder, autism spectrum disorder, anxiet

167 isorder, bipolar disorder, attention-deficit/hyperactivity disorder, autism spectrum disorder, intell

168 tism spectrum disorder and attention-deficit/hyperactivity disorder, but is much less so for bipolar

169 used extensively to treat attention deficit hyperactivity disorder, even though its effects on cogni

170 2; anxiety disorder, N=42; attention deficit hyperactivity disorder, N=40; and healthy volunteers, N=

171 ponent in the treatment of attention-deficit hyperactivity disorder, their use continues to prompt in

172 mptoms, anxiety disorders, attention-deficit hyperactivity disorder, Tourette syndrome, post-traumati

173 ptoms of schizophrenia and attention-deficit/hyperactivity disorder, which are characterized by impai

174 ons, with the exception of attention-deficit/hyperactivity disorder, which attenuated the risk of any

175 in patients with comorbid attention-deficit/hyperactivity disorder.

176 k of anxiety disorders and attention-deficit/hyperactivity disorder.

177 ons, eating disorders, and attention deficit/hyperactivity disorder.

178 typically associated with attention deficit hyperactivity disorder.

179 ve-compulsive disorder and attention-deficit hyperactivity disorder.

180 erity, tic medication, and attention deficit hyperactivity disorder.

181 ), schizophrenia (SZ), and Attention-Deficit-Hyperactivity-Disorder (ADHD), but their impact on funct

182 This hyperactivity disrupted the balance between excitation a

183 ropose that hippocampal glutamatergic neuron hyperactivity drives increased striatal dopaminergic act

184 This abnormal hyperactivity engages increasingly larger areas in a sal

185 NT Prior work suggested that age-related CA3 hyperactivity enhances pattern completion, resulting in

186 ic effects, but it decreased novelty-induced hyperactivity, exaggerated stereotypy, and vertical expl

187 cocaine pharmacokinetics and cocaine-induced hyperactivity for the first time.

188 ions of conduction block of peripheral nerve hyperactivity, for example in pain and spasticity.

189 behavioral and learning problems, lower IQ, hyperactivity, hearing problems, and impaired growth.

190 Vgat) neurons produces mania-like qualities (hyperactivity, hedonia, decreased sleep).

191 S-mitogen-activated protein kinase signaling hyperactivity, hypertrophic gene response and cellular h

192 behavioral abnormalities such as psychomotor hyperactivity, impaired learning and memory in the recip

193 In conclusion, chronic sympathetic hyperactivity impairs ECC by changing the density of sev

194 g-term behavioral abnormalities that include hyperactivity, impulsiveness, and motor incoordination.

195 nticipation and motor inhibition networks in hyperactivity, impulsivity, inattentive behaviour and co

196 g memory, focused attention), and finally to hyperactivity-impulsivity (working memory beta = -0.014

197 isk for ADHD was associated with symptoms of hyperactivity-impulsivity but not inattention.

198 Change in hyperactivity-impulsivity was associated with heritable

199 duals show some improvement, particularly of hyperactivity-impulsivity, symptoms of inattention are m

200 e = 0.09-0.91), an association with specific hyperactivity/impulsivity remained significant.

201 Hyperactivity/impulsivity symptoms were not related to m

202 , in addition to a specific association with hyperactivity/impulsivity symptoms.

203 We also found similar levels of hyperactivity/impulsivity, emotional lability, and impai

204 the sub-dimensions of ADHD - inattention and hyperactivity/impulsivity.

205 r and ~ 0.50% (p value < 0.0001) in specific hyperactivity/impulsivity.

206 river of the kidney abnormalities and mTORC1 hyperactivity in a mouse model of Birt-Hogg-Dube syndrom

207 Abnormal CA3 hyperactivity in aged rats has been proposed to contribu

208 of compulsive behaviors, which also exhibits hyperactivity in central striatum.

209 evalence of sympathetic nervous system (SNS) hyperactivity in diabetic patients makes them further su

210 we show loss of PLD blocks ethanol-mediated hyperactivity in Drosophila melanogaster (fruit fly), de

211 ts revealed a consistent spontaneous network hyperactivity in neurons deficient for CNTN5 or EHMT2.

212 Together with observations of hyperactivity in pre-SMA/SMA in both OCD and Tourette sy

213 model has been shown to depend on persistent hyperactivity in primary nociceptors (injury-detecting s

214 nopadol itself also dose-dependently induced hyperactivity in rats at doses higher than 50 ug/kg.

215 al nervous system, known to cause mania-like hyperactivity in rats.

216 eralized anxiety disorder is associated with hyperactivity in the amygdala-prefrontal networks, and n

217 the ventral hippocampus but did not prevent hyperactivity in the basolateral amygdala.

218 d memory deficits are correlated with neural hyperactivity in the CA3 region of the hippocampus.

219 t therapeutic hypotheses that depend on mTOR hyperactivity in the CNS.

220 d reduce suicidality, possibly by decreasing hyperactivity in the lateral habenula (LHb) brain nucleu

221 osensory cortex of young mice and behavioral hyperactivity in the mice at one minute after the loss o

222 Prepubertal EE also prevented hyperactivity in the ventral hippocampus but did not pre

223 Here, we demonstrate that CS-induced hyperactivity in ventral tegmental area (VTA)-projecting

224 crease in neuronal activation and behavioral hyperactivity in young mice.

225 crease in neuronal activation and behavioral hyperactivity in young mice.

226 symptoms were at higher risk for concomitant hyperactivity/inattention and emotional disorder, and ch

227 ties Questionnaire, which includes scales on hyperactivity/inattention, emotional problems, conduct p

228 In line with GLS hyperactivity, increased glutamate and decreased glutami

229 ctivity in the medial PFC, and that neuronal hyperactivity increases CSF1 signaling and alters microg

230 Here we show that chronic neuronal hyperactivity, induced by M-channel inhibition, triggere

231 ctively in BLBC tumors, indicating that CDK2 hyperactivity is a genome integrity vulnerability exploi

232 s such as posttraumatic stress disorder, PFC hyperactivity is associated with inappropriate fear in s

233 beta-amyloid (Abeta)-dependent neuronal hyperactivity is believed to contribute to the circuit d

234 Vagal hyperactivity is directly related to several clinical co

235 However, whether this localised hyperactivity is due to corticocortical inhibition or ex

236 Here, we show that age-related hyperactivity is present only in proximal CA3, with pote

237 Implicit in prior studies is the notion that hyperactivity is present throughout a functionally homog

238 It is not known whether age-related CA3 hyperactivity is uniformly represented along the CA3 tra

239 he mechanisms generating the disease-related hyperactivity, is a promising translational approach.

240 mitochondrial respiration, or "mitochondrial hyperactivity," is required for bcat-1(RNAi) neurotoxici

241 f 25 ug/kg (p.o.) did not induce significant hyperactivity itself, but significantly potentiated coca

242 onic chemogenetic attenuation of EC neuronal hyperactivity led to reduced hAPP/Abeta accumulation and

243 we present novel findings that neuronal mTOR hyperactivity levels correlate with the severity of epil

244 These data demonstrate that neuronal mTOR hyperactivity levels influence the severity of epilepsy

245 we examined the effects of differential mTOR hyperactivity levels on epilepsy and associated neuropat

246 her, our findings suggest that mitochondrial hyperactivity may be an early event in the pathogenesis

247 Hyperactivity occurred in neurons with preexisting basel

248 suggest that the pathogenesis of hippocampal hyperactivity occurs concurrent with the spread of tau p

249 ogen-deprivation therapy (ADT) would lead to hyperactivity of AKT.

250 latitude, and describe tumors with heritable hyperactivity of an endogenous mutational process.

251 hat selective REM sleep disturbance leads to hyperactivity of mHb ChNs, but also identify a key molec

252 thalamic stimulation normalizes pathological hyperactivity of motor cortex pyramidal cells, while con

253 ioid-mediated inhibition of cAMP and promote hyperactivity of nociceptors by enhancing C-Raf activity

254 ndromes are peripheral in origin and reflect hyperactivity of peripheral pain-signaling neurons.

255 Metabolic hyperactivity of plasmablasts resulted in nutrient depri

256 chronic restraint stress in mice results in hyperactivity of pro-opiomelanocortin neurons in the arc

257 ions such as depression or anxiety also have hyperactivity of the HPA axis.

258 nd screen that unmasked a previously unknown hyperactivity of the old antibiotic, rifabutin (RBT), ag

259 osensory cortex dysgranular zone (S1DZ), the hyperactivity of which was previously implicated in the

260 ut significantly potentiated cocaine-induced hyperactivity on Days 4 to 7 after the repeated daily do

261 The impact of cortico-striatal circuit hyperactivity on executive functions subserved by these

262 Loci of striatal hyperactivity recapitulated the spatial distribution of

263 The LD animals exhibited hyperactivity, reduced anxiety-like behavior, and defici

264 We hypothesized that glutamate hyperactivity, reflected by increased metabolic activity

265 d metabolic effects of chronic AgRP neuronal hyperactivity remain unexplored.

266 tions with added nitrate to rats resulted in hyperactivity reminiscent of human mania, alterations in

267 ceptibility to induced generalized seizures, hyperactivity, repetitive and reduced anxiety behaviours

268 Results indicated that hyperactivity responses to cocaine were absent in D1(-/-

269 In types 1 and 2 APDS, the PI3K-delta hyperactivity resulting from the gene mutations leads to

270 previously showed that loss of NORAD or PUM hyperactivity results in genome instability and prematur

271 ing loss with disyllable pronunciation only, hyperactivity, self-harm, hetero-aggressive behaviour, f

272 Exposure to PFHxA resulted in a unique hyperactivity signature.

273 FHM1 substitutions R192Q and S218L leads to hyperactivity similar to that of unc-2(zf35gf) mutants.

274 ited learning difficulties, impaired memory, hyperactivity, stereotyped and sometimes, maladaptive be

275 ion subscale and the CTRS-R:S ADHD index and hyperactivity subscale also deteriorated significantly m

276 es with depression, generalized anxiety, and hyperactivity symptoms at age 19.

277 depression, psychosis, and attention-deficit/hyperactivity symptoms.

278 -CoV-2 infection is associated with platelet hyperactivity, systemic inflammation, thrombotic complic

279 ssure overload of the heart, owing to mTORC1 hyperactivity that cannot be rescued by PKG1 stimulation

280 ilent soma were secondary to this peripheral hyperactivity that occurred without overt morphological

281 te symptoms of inattention, impulsivity, and hyperactivity that persist into adulthood in the majorit

282 etic hyperinnervation and sympathetic neural hyperactivity that persists despite normalization of LVE

283 nce of FMRP could contribute to the neuronal hyperactivity that underlies FXS.

284 wed gamma power abnormalities and behavioral hyperactivity that were consistent with observations rep

285 and exhibit genomic scars of Pol theta/TMEJ hyperactivity, thereby substantially expanding the subse

286 Together with the hyperactivity, this indicates that Ser482 is evolutionar

287 ine the clinical significance of hippocampal hyperactivity throughout the pathophysiological continuu

288 Bowen et al. (2019) show that targeting p53 hyperactivity to distinct compartments in vivo results i

289 nger timescale, AgRP neurons exhibit chronic hyperactivity under conditions of obesity and high dieta

290 motor effects suggests that stimulants drive hyperactivity via activation and inhibition of direct an

291 ne whether anesthetics can induce behavioral hyperactivity via increasing neuronal activation.

292 -independent Ca(2+) signals, whereas somatic hyperactivity was abolished.

293 Neuronal hyperactivity was found in the dentate gyrus (DG) of leu

294 Dopamine's role in hyperactivity was further highlighted by the finding tha

295 ctal spike frequency, sleep dysfunction, and hyperactivity was identified in Syngap1(+/-) mice.

296 To investigate the basis for the hyperactivity, we performed electrophysiological and imm

297 These phenotypes were the result of Tfap2a hyperactivity, where kctd15a/b-deficient embryos exhibit

298 acterized mouse model of chronic sympathetic hyperactivity, which are genetically deficient in the ad

299 t of BLA-PFC plasticity, probably due to BLA hyperactivity, which can also disrupt the reciprocal com

300 tivity and isoflurane only caused behavioral hyperactivity with borderline significance.